ELMMB logo
Facebook logo Twitter logo
Menu
MHRA Drug Safety Updates

MHRA Drug Safety Updates

MHRA Yellow Card Scheme: please help to reverse the decline in reporting of suspected adverse drug reactions 

Drug Safety Update MHRA Feb-2020-PDF.pdf

Drug Safety Update MHRA Feb-2020-PDF.pdf
Summary: Ingenol mebutate gel (Picato▼): suspension of the licence due to risk of skin malignancy. Lemtrada▼ (alemtuzumab): updated restrictions and strengthened monitoring requirements following review of serious cardiovascular and immune-mediated reactions.
File Size: 337KB
File Type: application/pdf
Created: 13 February 2020
Last Modified: 13 February 2020